A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

StatusActive, Not Recruiting

PhasePhase 3

SponsorUCB Biopharma SRL

Started2024-07-10

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Enrollment reduced 42% 120 → 70 participants

See other at-risk trials from UCB Biopharma SRL

Amendment history

2026-08-26

Study Status, Contacts/Locations v30

Trial sites reduced: 21 → 11 locations

2026-08-13

Study Status, Contacts/Locations v29

Study sites22→21

2026-07-16

Study Status v28

Re-verified, no change to tracked fields

2026-07-08

Study Status, Study Design, Contacts/Locations v27

Trial status changed: Recruiting → Active, Not Recruiting

Enrollment reduced: 120 → 70 participants

Primary completion moved earlier: 2030-03-01 → 2029-11-16

Completion moved earlier: 2030-03-01 → 2029-11-16

Study sites23→22

2026-06-18

Study Status, Contacts/Locations v26

Study sitesdetails revised at 4 of 23 sites

Show 25 earlier versions

2026-04-09

Study Status, Contacts/Locations v25

Study sitesdetails revised at 2 of 23 sites

2026-03-12

Study Status, Contacts/Locations v24

Study sitesdetails revised at 3 of 23 sites

2026-01-15

Study Status, Contacts/Locations v23

Study sitesdetails revised at 1 of 23 sites

2025-11-20

Study Status, Contacts/Locations v22

Study sitesdetails revised at 1 of 23 sites

2025-08-28

Study Status, Contacts/Locations v21

Study sitesdetails revised at 1 of 23 sites

2025-08-14

Study Status, Contacts/Locations v20

Study sitesdetails revised at 1 of 23 sites

2025-07-17

Study Status, Contacts/Locations v19

Study sites22→23

2025-03-27

Study Status, Contacts/Locations v18

Study sites21→22

2025-03-12

Study Status, Contacts/Locations v17

Study sites19→21

2025-02-13

Study Status, Contacts/Locations v16

Study sites18→19

2025-01-16

Study Status, Contacts/Locations v15

Study sitesdetails revised at 1 of 18 sites

2025-01-02

Study Status, Contacts/Locations v14

Study sites16→18

2024-12-20

Study Status, Contacts/Locations v13

Study sites15→16

2024-12-05

Study Status, Contacts/Locations v12

Study sites13→15

2024-11-21

Study Status, Contacts/Locations v11

Study sites11→13

2024-11-07

Study Status, Contacts/Locations v10

Study sites8→11

2024-10-24

Study Status, Contacts/Locations v9

Study sites7→8

2024-09-26

Study Status, Contacts/Locations v8

Study sites6→7

2024-09-12

Study Status, Contacts/Locations v7

Study sites2→6

2024-09-05

Study Status v6

Primary completion date2029-03-01→2030-03-01

Completion date2029-03-01→2030-03-01

2024-08-29

Study Status, Contacts/Locations v5

Study sites1→2

2024-07-25

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2024-07→confirmed 2024-07-10

Study sites0→1

2024-07-22

Study Status v3

Primary completion date2029-02-28→2029-03-01

Completion date2029-02-28→2029-03-01

Start date2024-06-14→2024-07

2024-05-27

Study Status v2

Start date2024-05→2024-06-14

2024-05-14

Study Status v1

Start date2024-04→2024-05

2024-03-11

Original filing

UCB Biopharma SRL

68 trials monitored

See 4 trials at risk

Epilepsy

723 trials monitored

See 41 trials at risk

The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.

Trial Details

NCT Number	NCT06315322
Lead Sponsor	UCB Biopharma SRL
Conditions	Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Enrollment	70 participants
Start Date	2024-07-10
Primary Completion	2029-11-16 (estimated)
Study Completion	2029-11-16 (estimated)
Updated on ClinicalTrials.gov	2026-08-27